PFE · Pfizer Inc · Documents

$28.89 +0.06 (+0.21%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$164.67B

5.70B

Volume · Nov 13 21.6M Avg daily vol (3M) 33.41M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $62.58B down 1.6% 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Revenue $16.58B down 0.4% 10-Q filed Nov 3, 2026 Latest results Revenue and adjusted EPS guidance raised 8-K filed Nov 3, 2026 Earnings call Q3 2026 earnings call Held Nov 3, 2026

2026

Nov 3

Current report 8-K Events of Oct 30

Cecile Guegan appointed Chief Financial Officer effective November 1, 2026

Pfizer named Cecile Guegan Chief Financial Officer effective November 1, 2026, following her interim role since August 16, 2026, with a $1,300,000 base salary and $1,300,000 annual target cash incentive.

Director or officer change, or executive pay

3 source passages

On November 3, 2026, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”). As reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2026, Ms. Guegan, 55, was previously appointed as the Company’s Interim Chief Financial Officer, effective August 16, 2026. (1) an annual base salary of $1,300,000; and (2) an annual target cash incentive opportunity of $1,300,000, which represents 100% of her annual base salary, which will be determined based on the salary paid during the year. Open the document at this passage

Nov 3

Earnings call

Guidance raised as non-COVID products grow

Pfizer reported third-quarter 2026 revenue of $16.6 billion, non-COVID operational growth of 7%, and raised full-year 2026 revenue guidance by $1.5 billion at the midpoint and adjusted diluted EPS guidance to $2.95-$3.05.

Read from the first part of this long document

4 source passages

Good morning, and welcome to Pfizer's earnings call. Start quarter 2026 revenue of $16.6 billion came in ahead of our expectation, with strong 7% operational revenue growth of our non-COVID products we are raising our full year 2026 revenue guidance by $1.5 billion at the midpoint We are raising and narrowing our full year 2026 adjusted diluted EPS guidance to a range of $2.95 to $3.05. Open the document at this passage

Nov 3

Quarterly report 10-Q FY2026 Q3, ended Sep 27

Nine-month revenue rose 2% as pretax income fell $3.3 billion

Pfizer Inc reported revenue of $46.1 billion, up 2%, while pretax income from continuing operations fell $3.3 billion to $5.9 billion. Expected cost realignment and manufacturing optimization savings rose to $6.7 billion and $3.0 billion through 2029.

Revenue $16.58B ▼ 0.4% Net income $3.24B ▼ 8.4% Diluted EPS $0.56 ▼ 9.7%

Read from the MD&A section

5 source passages

Pfizer Inc. is a research-based, global biopharmaceutical company. Total revenues increased $1.0 billion, or 2%, in the first nine months of 2026 to $46.1 billion from $45.0 billion in the first nine months of 2025, reflecting an operational increase of $412 million, or 1%, as well as a favorable impact of foreign exchange of $634 million, or 1%. The decrease in Income from continuing operations before provision/(benefit) for taxes on income of $3.3 billion, to $5.9 billion in the first nine months of 2026 from $9.2 billion in the first nine months of 2025, was primarily due to (i) charges for intangible asset impairments and certain legal matters, and increases in the fair value of our contingent consideration liabilities (all recorded in Other (income)/deductions––net), and (ii) increases in Research and development expenses, Cost of sales and Restructuring charges and certain acquisition-related costs, partially offset by (iii) a net gain in 2026 from the sale of our previous investment in ViiV (recorded in Other (income)/deductions––net), (iv) higher revenues, and (v) a decrease in Acquired in-process research and development expenses. With the additional anticipated savings, we now expect total net cost savings of approximately $6.7 billion from the program through 2029. With the additional anticipated savings, we now expect total net cost savings of approximately $3.0 billion from the program through 2029. Open the document at this passage

Nov 3

Current report 8-K

Revenue and adjusted EPS guidance raised

Pfizer Inc. reported third-quarter 2026 revenues of $16.6 billion, flat operationally year over year, and raised full-year 2026 revenue guidance to $62.0 to $64.0 billion and Adjusted diluted EPS guidance to $2.95 to $3.05.

Financial results Read from the first part of this long document

4 source passages

Third-Quarter 2026 Revenues of $16.6 Billion, Relatively Flat Year-over-Year Operationally Raises Full-Year 2026 Revenue Guidance(2) by $1.5 billion at the Midpoint to a Range of $62.0 to $64.0 billion Raises and Narrows Full-Year 2026 Adjusted(3) Diluted EPS Guidance to a Range of $2.95 to $3.05 Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance(2) for both Revenues and Adjusted(3) diluted EPS. Open the document at this passage

Sep 22

Investor event

J.P. Morgan U.S. All Stars 2026 Conference AI summary on its way

Sep 14

Investor event

Morgan Stanley 24th Annual Global Healthcare Conference AI summary on its way

Aug 4

Earnings call

Q2 2026 earnings call AI summary on its way

Aug 4

Current report 8-K

Financial results AI summary on its way